Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Stem Cells Therapy Market and Emerging Biotechnologies Industry Global Analysis in 2014 Report


News provided by

RnR Market Research

13 Nov, 2014, 12:30 GMT

Share this article

Share toX

Share this article

Share toX

DALLAS, November 13, 2014 /PRNewswire/ --

RnRMarketResearch.com adds PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy 2014 market research report of 250 pages to the stem cell and biotechnology industry research collection of its business intelligence library.

The PharmaSphere: Emerging Biotechnologies-Stem Cells 2014 market research report provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, South Korea, and Israel - providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook. Complete report is available at http://www.rnrmarketresearch.com/pharmasphere-emerging-biotechnologies-stem-cell-therapy-market-report.html .

Covering the worldwide stem cell market dynamics, this report provides analysis of the key drivers and trends shaping the global stem cell therapy industry, including manufacturing, emerging markets, and development pipeline. Financial Performance Insight is provided using data from across 22 key financial metrics to provide insight over stem cell company performance. Pipeline Analysis covering detailed information on ten leading stem cell therapies; trend analysis of clinical trial studies and investigators covering over 1000 trials related to stem cell therapies is also covered in this research. Exhaustive discussion on the strategic implications and synergies of deals including M&A, collaboration as well as capital raisings such as equity offerings, private equity and venture financing activities are mentioned in this report. Guidelines for stem cell usage for developing therapies in seven major markets for stem cells including US, Europe, Japan, SouthKorea, Israel, China and India as well as company landscape covering 40 companies on full pipeline, financials and key overview information are some of the highlights in this research.

Companies discussed in this stem cell therapy and emerging biotechnologies market report include Pharmicell, Mesoblast, Pluristem Therapeutics, NeoStem, Celgene Corporation, Cellerant Therapeutics, Cellular Biomedicine Group, K-Stemcell, Anterogen, Asterias Biotherapeutics, MediPost, Reliance Life Sciences, Stempeutics Research, Advanced Cell Technology, Athersys, Escape Therapeutics, Orbsen Therapeutics, Shenzhen Beike Biotechnology, Stem Cells, Bioheart, CHABio & Diostech, Cytomedix, Fate Therapeutics, Hygieia Innovation, Medistem, Neuralstem, Kasiak Research, ReNeuron, TiGenix, California Stem Cell, Capricor Therapeutics, GamidaCell, Histocell, Bone Therapeutics, Cardio3 BioSciences, Promethera Biosciences, Stemedica Cell Technologies, Tulane University, Brain Storm Cell Therapeutics and Cell Cure Neurosciences. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=240303 .

Benefits and reasons of buying this research include its data and information analysis that helps identify the key domestic players in various stem cell markets, including South Korea, Japan and emerging markets such as India and China. Understand the key drivers and trends in the global stem cell industry as well as analyze and track the strategies that companies are using to enter and/or strengthen their position in the evolving stem cell industry, as well as efforts being made by innovator companies like Pfizer and Novartis to enter this market. Readers can use this information as an independent source for your due diligence and transaction strategy and understand the regulatory framework and be prepared to tackle challenges facing the stem cell based therapies.

Questions on the stem cell market dynamics that this report helps answer include what are the key market drivers of the global stem cell industry? Who are the top players involved in the development of stem cell therapies in developed as well as developing countries? What are the main regulatory measures affecting the stem cell industry in the US, Europe, Japan, India, South Korea, China and Israel? What are the major trends in stem cell clinical trials and profiles of key investigators? What specific strategies are companies utilizing to combat some of the challenges currently facing the development of therapies in the global stem cell industry?

The stem cell pipeline in focus segment of this research covers information on Prochymal (Mesoblast), Adult Autologous CD34+ Stem Cells (Baxter), StemEx (Gamida Cell), Allogeneic MPC for Bone Marrow Transplantation (Mesoblast), Preob (Bone Therapeutics), Cerecellgram (Pharmicell), Revascor or CEP-41750 (Mesoblast), Tumor Stem Cell Specific Dendritic Cell Therapy (Neostem Oncology), GSK-2696273 (GlaxoSmithKline) and Lenti-D (Bluebird bio). This research is supported with 120 data tables and 51 figures to help with market analysis and intelligence information.

Other biotechnology industry reports on stem cell and relevant segments available with RnRMarketResearch.com include:

Stem Cell Research Products - Opportunities, Tools, and Technologies: This report does not look at the whole stem cell industry as if it was one marketplace, a mistake that every other stem cell report makes. As anyone working with stem cells knows, the stem cell market has two very distinct parts: stem cell therapies (the clinical applications of stem cells for medical purposes) and stem cell research products (the research tools and reagents that are used by scientists). It's the research products market you are interested in. So this entire report is geared toward helping you achieve success in developing and marketing stem cell research products. Full-year 2013 analysis determines the size of the stem cell research products market (including stem cell antibodies) to be $3.22 billion, and the stem cell therapies market to be $3.31 billion, for a total of $6.53 billion.

The Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 research report says the industry is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market. Complete report is available at http://www.rnrmarketresearch.com/stem-cell-therapy-market-by-treatment-mode-autologous-allogeneic-therapeutic-applications-cns-cvs-git-wound-healing-musculoskeletal-eye-immune-system-regulatory-landscape-pipeline-an-market-report.html .

Explore more reports on the stem cells market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology/stem-cell .

About Us: 

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.